Romaco completes virtual FAT for a blister machine
Despite current travel restrictions, the machine manufacturer manages to perform factory acceptance tests (FATs) via a live stream at its manufacturing facility.
Romaco is responding to the corona crisis by taking new approaches with the factory acceptance tests for its machines. The first Romaco Noack blister machine for a pharmaceutical producer in southern China has now passed its virtual FAT, which was carried out via a live stream.
In the light of current travel restrictions due to the COVID-19 pandemic, the pharmaceutical machinery manufacturer's customers are not allowed to attend the factory acceptance tests for their new equipment in person. Romaco has, therefore, begun carrying out FATs via a live stream or a video conferencing facility instead.
The first live remote FAT for a Noack blister machine was recently completed successfully at the Romaco manufacturing facility in Karlsruhe (Germany). This machine for a pharmaceutical producer in southern China can now be shipped and put into operation as planned.
The virtual FAT followed exactly the same procedure as its conventional counterpart. According to the FAT report, all tests relevant to production and safety were performed on the machine and streamed live.
Only half a day was required for the virtual acceptance of the Noack 623 blister machine, which will be used to seal ultra-lightweight and almost transparent hard gelatine capsules in aluminium–aluminium blisters. The people responsible at the customer end in China monitored the various functional tests closely during the live broadcast. The project manager in charge at Romaco China was at their side to translate any questions and answers straight away and ensure problem-free communication.
A blister line, complete with cartoner and case packer, is currently being acceptance-tested via a live link for a French manufacturer of contract packaging. Parallel to this, preparations are also underway for the FAT for two Romaco Siebler effervescent packaging lines destined for a pharmaceutical group in the US.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance